A Phase 2, Open Label, Multicenter, Randomized Study, to Evaluate the Efficacy and Safety of Denikitug Monotherapy and Denikitug-based Combinations in Participants With Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC).

Conditions

Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC)

Brief summary

ORR is defined as the percentage of participants who have achieved complete response (CR) or partial response (PR) as assessed by the investigator according to RECIST Version 1.1.

Detailed description

DOR is measured from the time of first response (CR or PR) as assessed by investigator, per RECIST Version 1.1 until the date of first documented progressive disease (PD) or death, whichever comes first., PFS is the time from date of randomization until PD or death from any cause, whichever comes first as assessed by the investigator according to RECIST Version 1.1., OS is length of time from randomization until the date of death from any cause., The incidence, severity, seriousness, and relatedness of treatment-emergent adverse events (TEAEs) and incidence and severity of clinical laboratory abnormalities graded according to National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0., Serum concentration of DEN and estimated PK parameters (eg, Cmax and AUCall), Percentage of treatment-emergent DEN ADA positive and ADA negative participants

Related papers

No related papers found yet.

Interventions

DRUGGS-1811 150 mg/vial concentrate for solution for infusion

DRUGLonsurf 15 mg/6.14 mg film-coated tablets

DRUGAvastin 25 mg/ml concentrate for solution for infusion.

DRUGOPDIVO 10 mg/mL concentrate for solution for infusion.

DRUGGS-1811

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
ORR is defined as the percentage of participants who have achieved complete response (CR) or partial response (PR) as assessed by the investigator according to RECIST Version 1.1.	—

Secondary

Measure	Time frame
DOR is measured from the time of first response (CR or PR) as assessed by investigator, per RECIST Version 1.1 until the date of first documented progressive disease (PD) or death, whichever comes first., PFS is the time from date of randomization until PD or death from any cause, whichever comes first as assessed by the investigator according to RECIST Version 1.1., OS is length of time from randomization until the date of death from any cause., The incidence, severity, seriousness, and relatedness of treatment-emergent adverse events (TEAEs) and incidence and severity of clinical laboratory abnormalities graded according to National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0., Serum concentration of DEN and estimated PK parameters (eg, Cmax and AUCall), Percentage of treatment-emergent DEN ADA positive and ADA negative participants	—

Measure

Time frame

DOR is measured from the time of first response (CR or PR) as assessed by investigator, per RECIST Version 1.1 until the date of first documented progressive disease (PD) or death, whichever comes first., PFS is the time from date of randomization until PD or death from any cause, whichever comes first as assessed by the investigator according to RECIST Version 1.1., OS is length of time from randomization until the date of death from any cause., The incidence, severity, seriousness, and relatedness of treatment-emergent adverse events (TEAEs) and incidence and severity of clinical laboratory abnormalities graded according to National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0., Serum concentration of DEN and estimated PK parameters (eg, Cmax and AUCall), Percentage of treatment-emergent DEN ADA positive and ADA negative participants

—

Outcome results

None listed